HK1120052A1 - Process for the preparation of glycosylated interferon beta - Google Patents

Process for the preparation of glycosylated interferon beta

Info

Publication number
HK1120052A1
HK1120052A1 HK08113888A HK08113888A HK1120052A1 HK 1120052 A1 HK1120052 A1 HK 1120052A1 HK 08113888 A HK08113888 A HK 08113888A HK 08113888 A HK08113888 A HK 08113888A HK 1120052 A1 HK1120052 A1 HK 1120052A1
Authority
HK
Hong Kong
Prior art keywords
interferon beta
preparation
glycosylated interferon
glycosylated
production
Prior art date
Application number
HK08113888A
Other languages
English (en)
Inventor
Dina Fischer
Alain Bernard
Paul Ducommun
Mara Rossi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of HK1120052A1 publication Critical patent/HK1120052A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
HK08113888A 2005-08-26 2008-12-23 Process for the preparation of glycosylated interferon beta HK1120052A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/054220 WO2007022799A1 (fr) 2005-08-26 2005-08-26 Procede de preparation d'interferon beta glycosyle

Publications (1)

Publication Number Publication Date
HK1120052A1 true HK1120052A1 (en) 2009-03-20

Family

ID=35788670

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113888A HK1120052A1 (en) 2005-08-26 2008-12-23 Process for the preparation of glycosylated interferon beta

Country Status (22)

Country Link
US (2) US20080219952A1 (fr)
EP (2) EP2390263A1 (fr)
JP (1) JP4944112B2 (fr)
KR (1) KR101276367B1 (fr)
CN (1) CN101282990B (fr)
AU (1) AU2005335900B2 (fr)
BR (1) BRPI0520498B8 (fr)
DK (1) DK1917276T3 (fr)
EA (1) EA015901B1 (fr)
ES (1) ES2664924T3 (fr)
HK (1) HK1120052A1 (fr)
HR (1) HRP20180579T1 (fr)
HU (1) HUE038947T2 (fr)
IL (1) IL189738A (fr)
LT (1) LT1917276T (fr)
MX (1) MX2008002596A (fr)
PL (1) PL1917276T3 (fr)
PT (1) PT1917276T (fr)
RS (1) RS57549B1 (fr)
SG (1) SG155183A1 (fr)
SI (1) SI1917276T1 (fr)
WO (1) WO2007022799A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
WO2008033517A2 (fr) 2006-09-13 2008-03-20 Abbott Laboratories Améliorations à la culture de cellules
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP2076533B1 (fr) 2007-05-02 2014-10-08 Ambrx, Inc. Polypeptides d'interferon beta modifies et leurs utilisations
JP2011500756A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ融合タンパク質を精製する方法
US20100256337A1 (en) * 2007-10-22 2010-10-07 Merck Serono Sa Method for purifying an fc-containing protein
DE102008051574A1 (de) * 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
EP2921501A1 (fr) * 2008-10-20 2015-09-23 Abbvie Inc. Isolement et purification d'anticorps par chromatographie d'affinité de la protéine A
WO2010089126A2 (fr) * 2009-02-09 2010-08-12 Roche Glycart Ag Analyse de motif de glycosylation d'immunoglobuline
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
US20120177603A1 (en) * 2009-07-07 2012-07-12 Biogenerix Ag Method for the purification of interferon-b
US20110136682A1 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
MY168902A (en) * 2011-10-01 2018-12-04 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
CN102533658B (zh) * 2011-12-08 2014-06-04 深圳新鹏生物工程有限公司 制备人干扰素β1a的细胞的培养方法和培养基及其应用
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
CN102757937B (zh) * 2012-07-05 2014-04-16 复旦大学附属中山医院 一种培养神经元的含酚红无血清培养体系以及酚红新用途
WO2014035475A1 (fr) 2012-09-02 2014-03-06 Abbvie Inc. Procédés de contrôle de l'hétérogénéité des protéines
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9169331B2 (en) 2012-12-21 2015-10-27 Dionex Corporation Separation of glycans by mixed-mode liquid chromatography
US9310344B2 (en) 2013-06-14 2016-04-12 Dionex Corporation HILIC/anion-exchange/cation-exchange multimodal media
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2015239104B2 (en) * 2014-04-04 2018-12-20 Ares Trading S.A. Novel IFN beta protein analogs
EA027609B9 (ru) * 2015-04-29 2017-11-30 Тютор С.А.С.И.Ф.И.А. Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа
EP3303559A1 (fr) * 2015-06-01 2018-04-11 Biogen MA Inc. Supplémentation en manganèse pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN111563198B (zh) * 2020-04-16 2023-07-25 百度在线网络技术（北京）有限公司 一种物料召回方法、装置、设备及存储介质
CN117024561B (zh) * 2023-10-10 2024-02-20 哈药集团生物工程有限公司 一种聚乙二醇修饰干扰素的纯化方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
CH648331A5 (de) 1979-07-31 1985-03-15 Hoffmann La Roche Homogenes fibroblasten-interferon und dessen herstellung.
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5266476A (en) 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
WO1990009800A1 (fr) * 1989-02-21 1990-09-07 Washington University Formes modifiees d'hormones de reproduction
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5665868A (en) 1990-09-14 1997-09-09 Vittal Mallya Scientific Research Foundation Chromatographic agent and its use for the separation or proteins, polypeptides of metals
RU2166955C2 (ru) 1991-01-18 2001-05-20 Эмген Инк. Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
US5508261A (en) * 1991-06-18 1996-04-16 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
DE4128319A1 (de) 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ATE501254T1 (de) 1992-10-23 2011-03-15 Genetics Inst Llc P- selectin ligandenprotein
EP0666312A1 (fr) 1994-02-08 1995-08-09 Wolfgang A. Renner Procédé pour l'amélioration de la croissance de cellules de mammifères
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
AU720337B2 (en) 1995-02-17 2000-05-25 Stichting Dienst Landbouwkundig Onderzoek Production of biologically active recombinant bovine follicle stimulating hormone (REC bFSH) in the baculovirus expression system
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
DE69623109T2 (de) 1996-04-19 2002-12-12 Nestle Sa Menschliche immortalisierte Colon-Epithelialzellen
JP2000517188A (ja) * 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
IT1287138B1 (it) 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
US6162905A (en) * 1996-11-07 2000-12-19 Ibsa Institut Biochimique S.A. FSH and LH separation and purification process
CZ300296B6 (cs) 1996-11-15 2009-04-15 Genentech, Inc. Zpusob izolace rekombinantního lidského neurotrofinu, neurotrofinový prostredek a zpusob cištení neurotrofinu
US5883073A (en) * 1997-04-03 1999-03-16 Washington University Single-chain double-alpha peptide
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EP1224940B2 (fr) 1997-09-23 2010-08-11 Rentschler Biotechnologie GmbH Formulations liquides d' interféron-bèta
US6414123B1 (en) 1997-10-21 2002-07-02 Vitro Diagnostics, Inc. Method for purifying FSH
US5990288A (en) * 1997-10-21 1999-11-23 Vitro Diagnostics, Inc. Method for purifying FSH
EA003789B1 (ru) 1998-04-28 2003-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
US20030153042A1 (en) 1998-07-28 2003-08-14 California Institute Of Technology Expression of functional eukaryotic proteins
ATE358139T1 (de) 1999-04-16 2007-04-15 Inst Massone S A Verfahren zur herstelllung von gonadotropin- zusammensetzungen
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
WO2001058493A1 (fr) 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
RS50416B (sr) 2000-02-22 2009-12-31 Laboratoires Serono Sa., Prečišćeni lh
JP2003530838A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20030017550A1 (en) * 2001-01-22 2003-01-23 Pang Danny Zhong Der DNA sequences encoding fusion proteins comprising IFN-beta and TM-alpha1
HUP0303251A2 (hu) * 2001-02-27 2003-12-29 Maxygen Aps Béta-interferon-szerű molekulák
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
AU784808B2 (en) 2001-04-02 2006-06-29 Kedrion Melville Inc. Prion and viral clearance process
CN1522159A (zh) * 2001-06-29 2004-08-18 马克西根公司 干扰素配制品
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7317095B2 (en) 2001-10-22 2008-01-08 Applied Research Systems Ars Holding N.V. Mutant glycoproteins
CA2471363C (fr) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Proteines hybrides d'albumine
JP2005519946A (ja) * 2002-03-12 2005-07-07 マキシジェン エーピーエス 発作の処置のためのインターフェロンβ様分子
CN101664545A (zh) 2002-07-17 2010-03-10 比奥根艾迪克Ma公司 使用干扰素-β治疗肾衰竭
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
UA88879C2 (en) 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
KR100524871B1 (ko) * 2003-12-04 2005-10-31 씨제이 주식회사 인터페론 베타의 정제방법
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
JP4763616B2 (ja) * 2003-12-22 2011-08-31 アレス トレーディング ソシエテ アノニム Ｆｓｈを精製するための方法
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
MX2007005327A (es) * 2004-11-09 2007-08-02 Ares Trading Sa Metodo para purificacion de la hormona foliculo estimulante (hfe).
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US7956034B2 (en) * 2006-01-17 2011-06-07 Merck Serono Sa FSH glycosylation variant D3N
JP2011500756A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ融合タンパク質を精製する方法
US20100256337A1 (en) * 2007-10-22 2010-10-07 Merck Serono Sa Method for purifying an fc-containing protein

Also Published As

Publication number Publication date
WO2007022799A1 (fr) 2007-03-01
AU2005335900A1 (en) 2007-03-01
IL189738A (en) 2012-07-31
JP2009505645A (ja) 2009-02-12
CN101282990A (zh) 2008-10-08
IL189738A0 (en) 2008-08-07
HUE038947T2 (hu) 2018-12-28
BRPI0520498A2 (pt) 2010-07-13
EA015901B1 (ru) 2011-12-30
EP2390263A1 (fr) 2011-11-30
AU2005335900B2 (en) 2012-03-29
EA200800669A1 (ru) 2008-12-30
PT1917276T (pt) 2018-06-11
US8993724B2 (en) 2015-03-31
MX2008002596A (es) 2008-03-14
KR101276367B1 (ko) 2013-06-25
SI1917276T1 (en) 2018-05-31
DK1917276T3 (en) 2018-05-07
HRP20180579T1 (hr) 2018-05-18
ES2664924T3 (es) 2018-04-24
BRPI0520498B8 (pt) 2021-05-25
CN101282990B (zh) 2013-04-03
JP4944112B2 (ja) 2012-05-30
KR20080048490A (ko) 2008-06-02
EP1917276B1 (fr) 2018-03-21
LT1917276T (lt) 2018-05-25
RS57549B1 (sr) 2018-10-31
EP1917276A1 (fr) 2008-05-07
SG155183A1 (en) 2009-09-30
PL1917276T3 (pl) 2018-08-31
US20110305669A1 (en) 2011-12-15
US20080219952A1 (en) 2008-09-11
BRPI0520498B1 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
HK1120052A1 (en) Process for the preparation of glycosylated interferon beta
PL1885753T3 (pl) Wytwarzanie rekombinowanego białka wiążącego IL-18
TWI349657B (en) Process for producing dichloropropanol
WO2007136752A3 (fr) Compositions d'érythropoïétine
WO2003104473A8 (fr) Galactosyl-isomalte, son procede de preparation et son utilisation
EP1950191A4 (fr) Procede de production de l'acide 3,3,3-trifluoropropionique
EP1559736A4 (fr) Procede de production de compositions de resine
SG109476A1 (en) Process for manufacturing prepreg
AU2003267565A8 (en) Process for the production of a fuel composition
EG23439A (en) Olefins production process.
EP1939184A4 (fr) Compose 1,3-diiodohydantoine et son procede de fabrication
EG23203A (en) Technical process for the manufacture of tropenol.
EP1930310A4 (fr) Procédé de production du 3,3,3-trifluoropropionaldéhyde
ZA200800044B (en) Process for the production of linear alpha-olefins
PL1627881T3 (pl) Sposób otrzymywania topiramatu
MXPA03008022A (es) Proceso para la produccion de polipeptidos.
ZA200801821B (en) Process for the preparation of glycosylated interferon beta
EP1935981A4 (fr) Processus destiné à produire une protéine recombinante
WO2002060263A3 (fr) Vinasse en boulangerie
HU0500396D0 (en) Process for producing 4,6-diamino-rezorcin dihydrochloride
HU0102594D0 (en) Process for production based on wheat known product with increased fibre content by baking technology
PL380041A1 (pl) Sposób wytwarzania kwasów , -alkilenodiamino-N,N'-bis(1-arylometylofosfonowych)
AR054152A1 (es) Procedimiento para la preparacion de interferon beta glicosilado
PL378553A1 (pl) Sposób wytwarzania (4aR,6R)-(-)-4,4a,5,6,7,8-heksahydro-6ß-hydroksy-4a-metylo-2(3H)-naftalenonu
AU2002318721A1 (en) Arrangement for production plant